Sample Document for Search:
Drugs in Development
suritozole
R&D Focus
October 09, 1995
- Originator:
- Hoechst Marion Roussel; (Germany); NA; NA;
NA
- Patent Assignee:
- Merrell Dow
- CAS® Registry Number:
- 110623-33-1
- Laboratory Code:
- MDL 26479
- Pharmacological Action:
- GABA agonist
- Therapeutic Class:
- Psychoanaleptics,
Antidepressants
- Nootropics
- Clinical Indications:
- depression
- cognitive defect
- Clinical Name:
- 2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-
3-thione
Latest Development: UPDATE: company merger.
- Highest Phase of Current Development:
- Phase II (40)
- Development Phase/Country/Indication:
- Phase II, USA
- Launch Date/Country:
- 19990000, USA
- Development History:
- 1993: Phase II, USA.
- AUG 1992:
Phase I/II, USA.
- SEP 1990: Preclinical, USA.
- 1985: Priority patent application filed,
USA.
Hoechst Marion Roussel (previously Marion Merrell Dow) is conducting phase II trials in the
USA with suritozole. This agent is a GABA inverse agonist and has potential for the treatment of
Alzheimer's disease, depression and dementia. HKS analysts predict a first launch in 1999 with potential
worldwide sales of US$200 million three to five years after first launch (MAY 1994). Merrell Dow has a
European patent claiming this compound.
Chronic administration of suritozole, unlike desipramine, causes a slowing of the firing rate
of Purkinje neurons. Suritozole also decreases noradrenergic enhancement of GABA-induced inhibition
of these neurons, as does desipramine. These results suggest that the antidepressant activity of suritozole
will be similar to that of desipramine, but with a faster onset of action.
Product: EP 221485 B 1990, priority US 792359 1985, designating 13 states. Equivalents
identified in 13 countries.
IMSWorld R&D Focus
© 1997 IMSWorld Publications Ltd. All rights reserved.
Dialog® File Number 445 Accession Number 2000929
Top
© 2008 Dialog LLC All Rights Reserved.